Progress on the diagnosis and treatment of infant acute myeloid leukemia
10.3760/cma.j.issn.1673-4408.2025.06.011
- VernacularTitle:婴儿急性髓细胞白血病诊疗进展
- Author:
Xingqing WANG
1
;
Tianyu LI
Author Information
1. 南京医科大学附属无锡人民医院 无锡市儿童医院血液科 214000
- Keywords:
Infant acute myeloid leukemia;
Molecular phenotype;
Hematopoietic stem cell transplantation;
Targeted therapy;
CAR-T cell therapy
- From:
International Journal of Pediatrics
2025;52(6):410-415
- CountryChina
- Language:Chinese
-
Abstract:
Infant acute myeloid leukemia（IAML）is a clinically rare hematological malignancy.Compared to older children，IAML patients usually have significantly higher-risk biological characteristics，namely a low induction remission rate and a high recurrence risk.Although continuous research has been conducted on its molecular mechanisms and treatment methods，the 5-year survival rate by traditional treatment regimens is only 50%~60%.Therefore，targeted therapies，such as CD33 monoclonal antibodies，and cellular immunotherapy，have become key strategies to overcome treatment barriers.This article reviews the progress on the molecular characteristics of IAML，the efficacy and challenges of traditional chemotherapy optimization schemes and targeted therapy，as well as CAR-T cell immunotherapy.
